Background/Aims: The aim of this paper is to report the treatment of type 2 nonproliferative idiopathic macular telangiectasia (IMT) with intravitreal bevacizumab (IVB). Methods: Retrospective case series of 10 eyes of 5 patients with type 2 IMT. All patients received 3 monthly IVB injections. Visual acuity (VA), fluorescein angiography (FA) and optical coherence tomography (OCT) were performed at baseline and 4 weeks after each injection. Results: Four weeks after the third IVB injection, VA remained stable for all patients. All eyes showed some decrease in fluorescein leakage, and there was a mild decrease in central macular thickness. One year later, VA, OCT and FA findings returned to the baseline levels. Conclusion: IVB did not improve VA in cases of type 2 IMT.

Keywords:
Idiopathic juxtafoveal retinal telangiectasia, Bevacizumab, Intravitreal injections
1.
Yannuzzi LA, Bardal AMC, Freund KB, Chen K, Eandi CM, Blodi B: Idiopathic macular telangiectasia. Arch Ophthalmol 2006;124:450–460.
2.
Kovach JL, Rosenfeld PJ: Bevacizumab (Avastin) therapy for idiopathic macular telangiectasia type II. Retina 2009;29:27–32.
3.
Charbel Issa P, Scholl HPN, Holz FG: Short-term effects of intravitreal bevacizumab in type II idiopathic macular telangiectasia. Retinal Cases Brief Rep 2007;4:189–191.
4.
Charbel Issa P, Holz FG, Scholl HP: Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 2007;114:1736–1742.
5.
Moon SJ, Berger AS, Tolentino MJ, Misch DM: Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. Ophthalmic Surg Lasers Imaging 2007;38:164–166.
6.
Toy BC, Koo E, Cukras C, Meyerle CB, Chew EY, Wong WT: Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab. Results of a phase II clinical trial. Retina 2012;32:996–1006.
7.
Charbel Issa P, Finger RP, Kruse K, Baumüller S, Scholl HP, Holz FG: Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol 2011;151:876–886.
8.
Roller AB, Folk JC, Patel NM, Boldt HC, Russell SR, Abramoff MD, Mahajan VB: Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 2011;31:1848–1855.
9.
Charbel Issa P, Finger RP, Holz FG, Scholl HP: Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 2008;92:941–945.
10.
Matt G, Sacu S, Ahlers C, Schütze C, Dunavoelgyi R, Prager F, Pruente C, Schmidt-Erfurth U: Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2. Eye 2010;24:1535–1541.
11.
Matsumoto Y, Yuzawa M: Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol 2010;54:320–324.
12.
Gamulescu MA, Walter A, Sachs H, Helbig H: Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2008;246:1189–1193.
13.
Surguch V, Gamulescu MA, Gabel VP: Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis. Arch Clin Exp Ophthalmol 2007;245:783–788.
14.
Lira RP, Silva VB, Cavalcanti TM, de Souza AC, Pinto AP: Intravitreous ranibizumab as treatment for macular telangiectasia type 2. Arch Ophthalmol 2010;128:1075–1078.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.